Results 251 to 260 of about 737,831 (320)

Synergistic drug combinations tend to improve therapeutically relevant selectivity

, 2009
Joseph Lehár, Andrew Krueger, William Avery, Adrian Heilbut, Lisa M. Johansen, Edward Price, Richard J. Rickles, Glenn F. Short, Jane Staunton, Xiaowei Jin, Margaret Lee, Grant R. Zimmermann, Alexis A. Borisy   +12 more
openalex   +2 more sources

Liver‐specific lncRNAs associated with liver cancers

FEBS Open Bio, EarlyView.
Long non‐coding RNAs (lncRNAs) are regulatory molecules with various functions. They are more tissue‐specific than proteins and can be used as potential biomarkers, particularly in cancer diagnostics and prognosis. In this review, we have systematically compiled all lncRNAs with exclusive expression in the human liver, verified their liver specificity ...
Olga Y. Burenina, Roman K. Makarchenko, Maria P. Rubtsova, Olga A. Dontsova   +3 more
wiley   +1 more source

The first-in-Africa ex vivo drug sensitivity testing platform identifies novel drug combinations for South African leukaemia patient cohort. [PDF]

Sci Rep
Kenmogne VL, Takundwa MM, Nweke EE, Monchusi B, Dube P, Maher H, Du Toit J, Philip-Cherian V, Fru PN, Thimiri Govinda Raj DB.   +9 more
europepmc   +1 more source

NMR screening of low molecular weight inhibitors targeting the papain‐like protease (PLPro) of SARS‐CoV‐2

FEBS Open Bio, EarlyView.
Papain‐like protease from SARS‐CoV‐2 plays an important role in the cleavage of the viral polyproteins and in the suppression of the host's immune response. Here, we present the results of an NMR screening study. We identified 86 binding compounds, of which five candidates were chosen for in‐depth analysis.
Dennis J. Pyper, Sridhar Sreeramulu, Benjamin T. Lanham, Elizabeth M. Engle, David Fushman, Harald Schwalbe   +5 more
wiley   +1 more source

Predicting effective drug combinations for cancer treatment using a graph-based approach. [PDF]

Synth Syst Biotechnol
Wang Q, Liu X, Yan G.
europepmc   +1 more source

Ro 31‐8220 suppresses bladder cancer progression via enhancing autophagy in vitro and in vivo

FEBS Open Bio, EarlyView.
The pan‐protein kinase C inhibitor Ro‐31‐8220 demonstrates potent anti‐bladder cancer effects both in vitro and in vivo by suppressing migration/invasion, inducing apoptosis and crucially activating autophagy, where blocking autophagy with chloroquine reduces its cell‐killing efficacy, suggesting its promise as a novel therapeutic candidate requiring ...
Shengjun Fu, Yan Tao, Shan Wu, Yuwen Gong, Youli Zhao, Shaomin Niu, Hui Cheng, You Mu, Na Xu, Ying Wang, Jianzhong Lu, Shanhui Liu, Lanlan Li   +12 more
wiley   +1 more source

Syn-COM: A Multi-Level Predictive Synergy Framework for Innovative Drug Combinations. [PDF]

Pharmaceuticals (Basel)
Shi Y, Liu J, Guan S, Wang S, Yu C, Yu Y, Li B, Zhang Y, Yang W, Wang Z.   +9 more
europepmc   +1 more source

Discontinuation of Immunotherapy in Patients With Relapsing Myelitis Without AQP4/MOG Antibodies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This study assesses the outcomes of immunotherapy discontinuation in patients with relapsing seronegative idiopathic myelitis (SIM), a condition that remains uninvestigated due to its rarity. We reviewed records from 77 patients with relapsing SIM at the National Cancer Center of Korea, focusing on 11 who discontinued treatment after a median ...
Ki Hoon Kim, You‐Ri Kang, Jae‐Won Hyun, Su‐Hyun Kim, Ho Jin Kim   +4 more
wiley   +1 more source

A network-based trans-omics approach for predicting synergistic drug combinations. [PDF]

Commun Med (Lond)
Iida M, Kuniki Y, Yagi K, Goda M, Namba S, Takeshita JI, Sawada R, Iwata M, Zamami Y, Ishizawa K, Yamanishi Y.   +10 more
europepmc   +1 more source

Identification and Exploration of Herb-Drug Combinations Used By Cancer Patients

, 2009
Silje Engdal, Olbjørn Klepp, Odd G. Nilsen   +2 more
openalex   +1 more source